 SQZ Biotechnologies Company NYSE: SQZ announced interim results from the highest-dose monotherapy cohort of Phase 12 trial of SQZ-PBMC-HPV in Human Papillomavirus positive HPV16 solid tumors. The investigational cell therapy is being evaluated in certain patients with advanced or metastatic HPV16 cancers. 